

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION No. 3813
TO BE ANSWERED ON THE 11th August, 2023

Strengthening of Pharmaceutical Industry Scheme

3813. SHRI G.M. SIDDESHWAR:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Government has recently issued any guidelines regarding “Strengthening of Pharmaceutical Industry” (SPI) scheme in Karnataka;
- (b) if so, the details thereof along with the details of funds allocated for the said scheme;
- (c) whether the Government also proposes to improve the existing infrastructural facilities of the pharma sector in Karnataka;
- (d) if so, the details thereof along with the targets fixed by the Government under the said scheme; and
- (e) the steps taken/proposed to be taken by the Government to establish India as a global leader in the pharma sector?

ANSWER

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(SHRI BHAGWANTH KHUBA)**

(a) to (d): Department of Pharmaceuticals, Government of India has released the guidelines for the scheme “Strengthening of Pharmaceutical Industry” (SPI) on 11.03.2022. The financial outlay of the Scheme is Rs. 500 Crores for the period from F.Y. 2021-22 to F.Y. 2025-26. The Scheme aims to address the rising demand for support to the existing Pharma clusters and MSMEs across the country to improve their productivity, quality, sustainability and to strengthen the existing infrastructure facilities in order to make India a global leader in Pharma sector. The scheme is applicable throughout the country and no state specific target is fixed.

The SPI Scheme has following three sub-schemes:

- i. **Assistance to Pharmaceutical Industry for Common Facilities (API-CF)** is provided to strengthen the existing pharmaceuticals clusters’ capacity for creating common facilities. This will not only improve the quality but also promote competitiveness and sustainable growth of the units in the cluster.
- ii. **Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)** aims to facilitate Micro, Small and Medium Pharma Enterprises (MSMEs) of proven track record to meet national and international regulatory standards (WHO-GMP or Schedule-M). Under the Scheme, interest subvention or capital subsidy on loan of such enterprises are provided, which further facilitates the growth in volumes as well as in quantity of these units, and
- iii. **Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)** to facilitate growth and development of Pharmaceuticals and Medical

Devices Sector through study/survey reports, awareness programs, creation of database, and promotion of industry.

(e): In addition to the SPI Scheme, Government of India has taken various measures to establish India as a global leader in the pharma sector. The Programmatic interventions in this regard are as follows:

- i. The *Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs)*, with a financial outlay of ₹ 6,940 crores over the tenure from FY 2020-2021 to FY 2029-30, for financial incentive provided for 41 identified products.
- ii. The *Production Linked Incentive (PLI) Scheme for Pharmaceuticals*, with a financial outlay Rs. 15,000 crores and the tenure from FY 2020- 2021 to FY 2028-29, provides for financial incentive to 55 selected applicants for manufacturing of eligible products falling under three product categories.
- iii. The *Scheme for support of setting up of Bulk Drug Parks* provides for support of upto Rs 1000 crore each for creating common infrastructure facilities in setting up of three Bulk Drug Parks.
